Hi timkiely, The first thing to note is that Vitrocard is the...

Hi timkiely,

The first thing to note is that Vitrocard is the "standard to compare" for us, but not the current standard of care. Vitrocard Margolis1 is what ftt's drug managed in the last trial (with those with Margolis1 categorised ulcers). This was a great result.

If we can replicate that in this large double blinded fda approved trial then that is great. It would prove our drug works.

The VF00102 arms are those on the current trial. A third are on low (standard) dose, a third on high dose and a third on placebo. The data includes all.

The slight concern one could have is not that the VF00102 arms are under performing, but that they are over performing. Because one would expect that the third of placebo subjects would reduce the improvement a bit. Historically the placebo normally shows some improvement in these kinds of trials. We don't want the placebo to do as well as the drug!

But we do have a higher dose arm, 10 times stronger than before, so maybe that is helping our figures.

All imho. I hope that helps.

Cheers